Bicara Therapeutics BCAX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$56.21M-50.4% | -$37.39M-2.9% | -$36.33M-32.6% | -$27.39M+25.7% | -$36.85M-75.8% | ||
| $44K+2.3% | $43K+79.2% | $24K+26.3% | $19K0.0% | $19K+26.7% | ||
| $5.86M+31.7% | $4.45M+23.1% | $3.61M+3.5% | $3.49M+1.2% | $3.45M+8.5% | ||
| -$2.09M-149% | -$839K— | $0+100% | -$627K+84.8% | -$4.12M-125% | ||
| $273K— | —— | $249K+18.0% | $211K+52.9% | $138K— | ||
| -$270K+7.5% | -$292K+7.9% | -$317K-80.1% | -$176K-19.7% | -$147K-150% | ||
| -$37.51M-57.0% | -$23.89M+18.3% | -$29.25M-14.3% | -$25.59M+8.9% | -$28.11M+6.4% | ||
| $60K-74.8% | $238K+467% | $42K— | $0— | $0-100% | ||
| $101M— | —— | —— | —— | $0— | ||
| $100.94M+223% | -$82.33M+65.1% | -$236.12M— | $0— | $0+100% | ||
| $161.76M+448% | $29.5M+5,058% | -$595K-200% | $595K— | $0— | ||
| $163.35M+423% | $31.23M+7,063% | $436K+223% | $135K-70.7% | $460K— | ||
| $226.78M+402% | -$74.99M+71.7% | -$264.93M-941% | -$25.46M+7.9% | -$27.65M-143% | ||
| $0— | —— | $167K+221% | $52K-27.8% | $72K— | ||
| -$338K-25.7% | -$269K— | —— | —— | $0— | ||
| $44K+2.3% | $43K+79.2% | $24K+26.3% | $19K0.0% | $19K+26.7% | ||
| -$270K+7.5% | -$292K+7.9% | -$317K-80.1% | -$176K-19.7% | -$147K-150% | ||
| -$2.09M-149% | -$839K— | $0+100% | -$627K+84.8% | -$4.12M-125% | ||
| $273K— | —— | $249K+18.0% | $211K+52.9% | $138K— | ||
| —— | $223.75K0.0% | $223.75K0.0% | $223.75K0.0% | $223.75K+1,262% | ||
| $101M— | —— | —— | —— | $0— | ||
| $190K— | —— | $0— | $0— | $0— | ||
| -$37.57M-55.7% | -$24.12M+17.6% | -$29.29M-14.4% | -$25.59M+8.9% | -$28.11M+6.5% | ||
| -$37.57M-55.7% | -$24.12M+17.6% | -$29.29M-14.4% | -$25.59M+8.9% | -$28.11M+6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Bicara Therapeutics's cash flow data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.